Effect of IV Cangrelor vs PO Ticagrelor on myocardial damage in STEMI
Research type
Research Study
Full title
The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients admitted with STEMI Treated by Primary Percutaneous Coronary Intervention A randomized controlled pilot trial
IRAS ID
193942
Contact name
James Cotton
Contact email
Sponsor organisation
The Royal Wolverhampton NHS Trust
Eudract number
2016-000195-19
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
If you have a major heart attack (myocardial infarction), a coronary artery is suddenly blocked due to clot formation. Blood clots do not usually form in normal arteries. However, a clot may form if there is some furring up within the lining of heart arteries. These clots are largely made of sticky blood cells called platelets that in health repair blood vessels and prevent natural bleeding. One of the main goals of drug therapy in patients with major heart attacks is to break up blood clots by making these sticky blood cells less sticky (antiplatelet effect).
Aspirin is the main oral anti-platelet agent used in the UK. In addition to Aspirin, we currently use a new oral antiplatelet agent called Ticagrelor. Increasing clinical evidence suggests that in the setting of major heart attacks, the oral antiplatelet drugs are poorly absorbed and have little effect at the time of most need i.e. soon after antiplatelet agents administration while the primary PCI is being performed (PCI, a procedure performed through arteries in the arm or groin under local anaesthetics to open up blocked arteries using special tubes called catheters, a thin wire, balloon and mesh-type of tubes called stents). Normally, it can take up to 2 hours for the antiplatelet agents to produce adequate effect. In heart attack patients primary PCI is usually performed well within this timescale and a faster acting antiplatelet is therefore needed.In our study, we will be testing the effect of a newer fast-acting intravenous antiplatelet agent called Cangrelor against Ticagrelor (the standard oral antiplatelet agent given to patients with major heart attacks). Cangrelor has been licenced in the USA, Europe and UK to be given in patients with heart attack.
The effect of these two antiplatelet agents will be measured using various blood tests and scans.REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
16/EM/0094
Date of REC Opinion
25 Mar 2016
REC opinion
Further Information Favourable Opinion